Cost Could Drag On Lilly's Baricitinib Outlook Despite Deepening Data
This article was originally published in Scrip
Executive Summary
Eli Lilly & Co. and partner Incyte Corp. have added to the growing dataset for their once-daily oral JAK1/JAK2 inhibitor baricitinib ahead of their planned filing by year-end, with detailed results from the pivotal Phase III RA-BEAM which showed the investigational therapy had superior patient-reported outcomes compared with AbbVie's market-leading injectable anti-TNF antibody, Humira (adalimumab), along with better response claims and structural improvements for patients.